<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548633" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548633/" /><meta name="ncbi_pagename" content="Adefovir - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Adefovir - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Adefovir" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2016/02/15" /><meta name="citation_pmid" content="31643945" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548633/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Adefovir" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2016/02/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548633/" /><meta name="description" content="Adefovir dipivoxil is an acyclic nucleotide analogue of adenosine used either alone or in combination with other agents as therapy of chronic hepatitis B. Adefovir does not appear to be a significant cause of drug induced liver injury, but initiation of therapy and sudden withdrawal of therapy can induce a transient exacerbation of the underlying hepatitis B." /><meta name="og:title" content="Adefovir" /><meta name="og:type" content="book" /><meta name="og:description" content="Adefovir dipivoxil is an acyclic nucleotide analogue of adenosine used either alone or in combination with other agents as therapy of chronic hepatitis B. Adefovir does not appear to be a significant cause of drug induced liver injury, but initiation of therapy and sudden withdrawal of therapy can induce a transient exacerbation of the underlying hepatitis B." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548633/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Adefovir/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548633/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B320904669E3100000000027E00C5.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548633_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548633_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Adalimumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Afatinib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548633_"><span class="title" itemprop="name">Adefovir</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 15, 2016</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Adefovir.OVERVIEW"><h2 id="_Adefovir_OVERVIEW_">OVERVIEW</h2><div id="Adefovir.Introduction"><h3>Introduction</h3><p>Adefovir dipivoxil is an acyclic nucleotide analogue of adenosine used either alone or in combination with other agents as therapy of chronic hepatitis B. Adefovir does not appear to be a significant cause of drug induced liver injury, but initiation of therapy and sudden withdrawal of therapy can induce a transient exacerbation of the underlying hepatitis B.</p></div><div id="Adefovir.Background"><h3>Background</h3><p>Adefovir dipivoxil (bis-pom PMEA) is an acyclic nucleotide analog and prodrug of adefovir (a def' oh vir). The dipivoxil moiety is hydrolyzed after absorption, and adefovir is phosphorylated intracellularly to its active form, adefovir triphosphate, which competes with deoxyadenosine triphosphate for incorporation into the growing HBV DNA strand, causing inhibition of the viral DNA polymerase and chain termination. Adefovir is indicated for the treatment of chronic hepatitis B as a single agent and with lamivudine for lamivudine-resistant HBV infection. Adefovir was approved by the FDA in 2002 as therapy for hepatitis B. Adefovir is available generically and under the brand name Hepsera in 10 mg tablets. The recommended dose of adefovir is 10 mg orally once daily in adults and children age 12 years and older. The dose should be adjusted for renal impairment. Adefovir has minimal activity against human immunodeficiency virus (HIV) infection and is considered contraindicated in patients with HBV-HIV coinfection. Recently, adefovir has been largely replaced by tenofovir which has a similar mechanism and spectrum of activity, but is approximately 30 times more potent against HBV. Side effects of adefovir include asthenia and renal injury which is marked by increases in serum creatinine levels, hypophosphatemia, hypouricemia and renal tubular acidosis.</p></div><div id="Adefovir.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Serum aminotransferase elevations are common during or after therapy of hepatitis B, but appear to be due to exacerbations of the underlying HBV infection rather than hepatotoxicity. Sudden withdrawal of adefovir therapy can lead to an acute flare of hepatitis as viral levels suddenly rise. These withdrawal flares are usually transient and self-limited, but in rare instances are symptomatic and severe and can lead to death or need for liver transplantation. Instances of moderate serum aminotransferase elevations early during treatment have been described in clinical trials, but these elevations are usually transient and asymptomatic and are found in up to 25% of persons who start nucleoside analogue therapy of hepatitis B. Finally, development of antiviral resistance can be followed by a flare of the underlying hepatitis B as HBV DNA levels rise. Antiviral resistance to adefovir is rare during the first 1 to 2 years of therapy, but increasing rates are found with long-term therapy.</p><p>Adefovir has not been associated with cases of lactic acidosis with hepatic steatosis and liver failure. Tenofovir, a nucleotide analogue similar to adefovir, has been associated with isolated cases of lactic acidosis, but only in combination with other antiretroviral agents that are more closely linked to this syndrome. Because adefovir is considered contraindicated in HIV infection (it has weak anti-HIV activity), it is not used in combination with typical antiretroviral drugs. There have been no convincing cases of lactic acidosis or of clinically apparent liver injury with symptoms or jaundice due to adefovir.</p><p>Likehood score: E (unlikely cause of clinically apparent, idiosyncratic liver injury).</p></div><div id="Adefovir.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The apparent absence of significant hepatotoxicity from adefovir may be due to its minimal hepatic metabolism and rapid urinary excretion. In vitro, adefovir demonstrates little inhibitory activity against mitochondrial polymerase gamma.</p></div><div id="Adefovir.Outcome_and_Management"><h3>Outcome and Management</h3><p>The mild-to-moderate <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations associated with initiating adefovir use are usually asymptomatic and transient. Due to the high percentage of patients who have flares of hepatitis B after discontinuation of adefovir, serum aminotransferase testing should be monitored for several months and antiviral therapy resumed if symptoms or jaundice arise or serum aminotransferases remain significantly above baseline (pretreatment) levels. Patients who develop antiviral resistance to adefovir can have significant flares of hepatitis B and should be switched to or have added another agent with a different profile of resistance.</p><p>[Agents used in therapy of HBV infection include adefovir, emtricitabine, entecavir, lamivudine, telbivudine, tenofovir, interferon alfa and peginterferon.]</p><p>Drug Class: <a href="/books/n/livertox/AntiviralAgents/">Antiviral Agents</a>, Antiretroviral Agents, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.hepatitis-b/">Hepatitis B</a> Agents</p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/NucleosideAnalogues/">Nucleoside Analogues</a>: <a href="/books/n/livertox/Abacavir/">Abacavir</a>, <a href="/books/n/livertox/Didanosine/">Didanosine</a>, <a href="/books/n/livertox/Emtricitabine/">Emtricitabine</a>, <a href="/books/n/livertox/Entecavir/">Entecavir</a>, <a href="/books/n/livertox/Lamivudine/">Lamivudine</a>, <a href="/books/n/livertox/Stavudine/">Stavudine</a>, <a href="/books/n/livertox/Telbivudine/">Telbivudine</a>, <a href="/books/n/livertox/Tenofovir/">Tenofovir</a>, <a href="/books/n/livertox/Zidovudine/">Zidovudine</a></p></div></div><div id="Adefovir.CASE_REPORT"><h2 id="_Adefovir_CASE_REPORT_">CASE REPORT</h2><div id="Adefovir.Case_1._Flare_of_hepatitis_B_ac"><h3>Case 1. Flare of hepatitis B accompanying development of adefovir resistance.</h3><p>[NIH Case: Adefovir-Lamivudine #6]</p><p>A 56 year old man with chronic hepatitis B and previous therapy with interferon and lamivudine was treated with adefovir (10 mg daily). He took no other medications and did not drink alcohol. He had no symptoms of hepatitis, but appeared to have Gilbert&#x02019;s syndrome with intermittently elevated total bilirubin levels, but normal direct fractions. He was positive for HBsAg and HBeAg in serum and HBV DNA levels were high. Molecular testing revealed evidence of lamivudine-resistant virus (rtM204V/rtL180M). <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels were only modestly elevated (Table). A liver biopsy showed moderate histological activity and bridging hepatic fibrosis. With adefovir therapy, serum HBV DNA levels decreased by only 3 to 4 log10 copies per mL and ALT levels improved minimally. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.liver-histology/">Liver histology</a> did not change. He remained asymptomatic and had no other medical problems. During the third year of therapy, HBV DNA levels began to rise towards pretreatment values and serum ALT levels increased five-fold. Molecular testing showed presence of the typical adefovir-resistant mutation in the HBV polymerase gene: rtN236T. Switching therapy to tenofovir led to prompt decrease in HBV DNA levels and improvements in ALT values.</p><div id="Adefovir.Key_Points"><h4>Key Points</h4><div id="Adefovir.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548633/table/Adefovir.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Adefovir.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Adefovir.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Adefovir (10 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Adefovir.T1_1_1_1_1" id="hd_b_Adefovir.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Adefovir.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular</td></tr><tr><th headers="hd_h_Adefovir.T1_1_1_1_1" id="hd_b_Adefovir.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Adefovir.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">1+ (aminotransferase elevations without jaundice)</td></tr><tr><th headers="hd_h_Adefovir.T1_1_1_1_1" id="hd_b_Adefovir.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Adefovir.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">3 years</td></tr><tr><th headers="hd_h_Adefovir.T1_1_1_1_1" id="hd_b_Adefovir.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Adefovir.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">After switching to tenofovir therapy</td></tr><tr><th headers="hd_h_Adefovir.T1_1_1_1_1" id="hd_b_Adefovir.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Adefovir.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr></tbody></table></div></div></div><div id="Adefovir.Laboratory_Values"><h4>Laboratory Values</h4><div id="Adefovir.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548633/table/Adefovir.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Adefovir.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> (U/L)</th><th id="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">HBV DNA (copies/mL)</th><th id="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">55</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">95</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.7</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">456,000,000</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6 months</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">46</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">105</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.6</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">892,000</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">1 year</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">48</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">90</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.7</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">489,000</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">Liver biopsy</td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 years</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">45</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">108</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.7</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">120,000</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3 years</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">33</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">114</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.2</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">121,506</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">3.7 years</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">43</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">94</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.2</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">132,026,000</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;">rtN236T mutation</td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">4 years</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">205</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">98</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.9</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">31,349,600</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1 hd_h_Adefovir.T2_1_1_1_2 hd_h_Adefovir.T2_1_1_1_3 hd_h_Adefovir.T2_1_1_1_4 hd_h_Adefovir.T2_1_1_1_5 hd_h_Adefovir.T2_1_1_1_6 hd_h_Adefovir.T2_1_1_1_7" colspan="7" rowspan="1" style="vertical-align:top;">Switched to tenofovir therapy (300 mg daily)</td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">2 months*</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 months</td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">61</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">108</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.5</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">1,715</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">6months*</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">6 months</td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">27</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">129</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.5</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">&#x0003c;58</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">5 years*</td><td headers="hd_h_Adefovir.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">5 years</td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">25</td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">130</td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.5</td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">&#x0003c;10</td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Adefovir.T2_1_1_1_1 hd_h_Adefovir.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Adefovir.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Adefovir.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Adefovir.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Adefovir.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Adefovir.T2_1_1_1_7" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div><p>*Time after switching to tenofovir</p></div><div id="Adefovir.Comment"><h4>Comment</h4><p>Adefovir therapy of chronic hepatitis B is associated with a low rate of antiviral resistance during the first 1 to 2 years of treatment, but a somewhat high rate of poor initial response (as in this patient). Antiviral resistant rates increase to 17% to 28% after 3 to 4 years of treatment. Development of virological breakthrough is commonly followed by a flare in the underlying hepatitis. In this patient, the flare was mild and the adefovir-resistant virus was successfully suppressed by tenofovir therapy. These features make monotherapy with adefovir problematic in chronic hepatitis B and it is now rarely used.</p></div></div></div><div id="Adefovir.PRODUCT_INFORMATION"><h2 id="_Adefovir_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Adefovir.BPI" class="box"><p><b> REPRESENTATIVE TRADE NAMES</b></p><p>Adefovir &#x02013; Hepsera&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiviral Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=adefovir" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Adefovir.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Adefovir_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Adefovir.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548633/table/Adefovir.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Adefovir.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Adefovir.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Adefovir.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Adefovir.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Adefovir.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Adefovir.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Adefovir</td><td headers="hd_h_Adefovir.T3_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135016825" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">106941-25-7</a></td><td headers="hd_h_Adefovir.T3_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C8-H12-N5-O4-P</td><td headers="hd_h_Adefovir.T3_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548633/bin/Adefovir_Structure.jpg" alt="Adefovir Chemical Structure" /></div></td></tr></tbody></table></div></div></div><div id="Adefovir.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Adefovir_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 15 February 2016</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Adefovir.R1">N&#x000fa;&#x000f1;ez M. Hepatitis treatments. Hepatic toxicity of antiviral agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 511-2.<div><i>(Review of hepatotoxicity of antiviral agents; mentions the potential of severe flares of disease upon withdrawal of therapy in chronic hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R2">Acosta EP, Flexner C. Antiviral agents (nonretroviral). In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1593-1622.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R3">Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, et al. A placebo-controlled phase I/II study of Adefovir dipivoxil in patients with chronic hepatitis B virus infection. J Viral Hepat 1999; 6: 387-95.  [<a href="/pubmed/10607255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10607255</span></a>]<div><i>(Controlled trial of high doses of adefovir [125 mg/day] vs placebo in 20 patients with chronic hepatitis B; ALT elevations of 724 U/L and 980 U/L occurred in 2 patients early during therapy and elevations above 300 U/L in 4 after withdrawal; none developed jaundice).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R4">Marcellin P, Change TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, et al.; Adefovir Dipivoxil 437 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.  [<a href="/pubmed/12606735" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12606735</span></a>]<div><i>(Controlled trial of adefovir vs placebo for 48 weeks in 515 patients with HBeAg-positive chronic hepatitis B: ALT elevations &#x0003e;10 times ULN occurred in 9% of adefovir vs 19% placebo recipients; in the adefovir group, no patient had jaundice or needed to stop therapy for ALT elevations).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R5">Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, et al.; Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7. Erratum in: N Engl J Med 2003; 348: 1192.  [<a href="/pubmed/12606734" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12606734</span></a>]<div><i>(Controlled trial of adefovir vs placebo for 48 weeks in 185 patients with HBeAg-negative chronic hepatitis B; one placebo- but no adefovir-treated patient had severe flare of hepatitis).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R6">Rivas P, Polo J, de G&#x000f3;rgolas M, Fern&#x000e1;ndez-Guerrero ML. Drug Points: Fatal lactic acidosis associated with tenofovir. BMJ 2003, 327: 711.  [<a href="/pmc/articles/PMC200801/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC200801</span></a>] [<a href="/pubmed/14512477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14512477</span></a>]<div><i>(45 year old woman with HIV-HCV coinfection developed jaundice and lactic acidosis on tenofovir [8 weeks], didanosine and stavudine [long term] [bilirubin 12.6 mg/dL, ALT 157 U/L], with progressive liver failure and death; role of tenofovir vs didanosine and stavudine uncertain).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R7">Murphy MD, O.Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. CID 2003; 36: 1982-6.  [<a href="/pubmed/12684925" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12684925</span></a>]<div><i>(49 year old man with HIV and renal insufficiency on long term didanosine developed progressive, fatal lactic acidosis 6 weeks after starting tenofovir; lactate of 5.5 rising to 16.7 mM; no mention of liver injury).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R8">Guo Y, Fung HB. Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. Pharmacotherapy 2004; 24: 1089-94.  [<a href="/pubmed/15338857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15338857</span></a>]<div><i>(63 year old man with HIV and HCV developed fatal lactic acidosis 1.5 years after starting didanosine-tenofovir-lopinavir-ritonavir regimen, with pancreatitis, multiorgan failure and death; liver injury not mentioned).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R9">Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 2005; 11: 3697-710.  [<a href="/pubmed/16305505" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16305505</span></a>]<div><i>(Review of risk factors, epidemiology and pathogenic mechanisms of hepatotoxicity caused by antiretroviral drugs).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R10">Masi&#x000e1; M, Guti&#x000e9;rrez F, Padilla S, Ramos JM, Pascual J. Severe toxicity associated with the combination of tenofovir and didanosine: case report and review. Int J STD AIDS 2005; 16: 646-8.  [<a href="/pubmed/16176639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16176639</span></a>]<div><i>(45 year old with HIV-HCV coinfection developed lactic acidosis and "mild cholestasis" 3 months after adding tenofovir to didanosine, resolving slowly after stopping therapy).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R11">Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, et al.; Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131: 1743-51.  [<a href="/pubmed/17087951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17087951</span></a>]<div><i>(Results after 2 years in 185 HBeAg-negative chronic hepatitis B; 13 of 38 [32%] patients who stopped adefovir after 1 year had rise in ALT &#x0003e;10 times ULN, one with jaundice).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R12">Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, et al.; Adefovir Dipivoxil Study 45 International Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.  [<a href="/pubmed/17326221" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17326221</span></a>]<div><i>(Among 226 pre- and 241 post-transplant patients with chronic hepatitis B treated with adefovir for up to 2 years, ALT elevations occurred in 2-4%; none considered serious or requiring drug discontinuation).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R13">Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, et al.; 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745-54.  [<a href="/pubmed/17909201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17909201</span></a>]<div><i>(Controlled trial of telbivudine vs adefovir in 135 patients with HBeAg-positive chronic hepatitis B, mild transient elevations in ALT occurred in both groups).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R14">Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.  [<a href="/pubmed/18752330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18752330</span></a>]<div><i>(Among 65 patients with HBeAg-positive chronic hepatitis B treated for up to 5 years, 9% had ALT elevation above 5 times ULN, all resolving without change in therapy).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R15">Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.  [<a href="/pubmed/19052126" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19052126</span></a>]<div><i>(Two controlled trials of tenofovir vs adefovir in 641 patients with chronic hepatitis B; ALT levels above 5 times ULN occurred in 6% of tenofovir and 3% of adefovir recipients, usually within 8 weeks of starting; all were self-limited even with continuing drug).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R16">Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl): S185-95.  [<a href="/pubmed/19399802" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19399802</span></a>]<div><i>(Review of side effects of nucleoside analogues used to treat chronic hepatitis B).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R17">Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Liang JT, Ghany MG, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 2012; 35: 1317-25.  [<a href="/pmc/articles/PMC3443969/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3443969</span></a>] [<a href="/pubmed/22506503" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22506503</span></a>]<div><i>(Among 51 patients with chronic hepatitis B treated with adefovir or tenofovir for 1 to 10 years, 7 [14%] developed renal tubular dysfunction).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R18">Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, et al. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther 2012 Mar 26. [Epub ahead of print]  [<a href="/pmc/articles/PMC7448290/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7448290</span></a>] [<a href="/pubmed/22449251" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22449251</span></a>]<div><i>(Controlled trial of adefovir alone vs its combination with lamivudine in 41 patients with chronic hepatitis B treated for up to 4 years demonstated a better long term response rate with the combination; no hepatotoxicity mentioned).</i></div></div></li><li><div class="bk_ref" id="Adefovir.R19">Antiviral drugs. Treat Guidel Med Lett 2013; 11 (127): 19-30.  [<a href="/pubmed/23459414" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23459414</span></a>]<div><i> (Review of safety and efficacy of antivirals used to treated hepatitis B mentions that acute flares of hepatitis B occur in up to 25% of patients who discontinue adefovir). </i></div></div></li><li><div class="bk_ref" id="Adefovir.R20">Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016; 63: 261-83.  [<a href="/pmc/articles/PMC5987259/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5987259</span></a>] [<a href="/pubmed/26566064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26566064</span></a>]<div><i> (Guidelines for management and treatment of hepatitis B from the American Association for the Study of Liver Diseases lists adefovir as an approved oral therapy of chronic hepatitis B).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548633</span><span class="label">PMID: <a href="/pubmed/31643945" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643945</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Adalimumab/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Afatinib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548633&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548633/?report=reader">PubReader</a></li><li><a href="/books/NBK548633/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548633" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548633" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Adefovir. [Updated 2016 Feb 15].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548633/pdf/Bookshelf_NBK548633.pdf">PDF version of this page</a> (111K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(Adefovir/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Adefovir: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Adefovir" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Adefovir: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4857122" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4857122" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4857122" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14997399" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.</a><span class="source">[Z Gastroenterol. 2004]</span><div class="brieflinkpop offscreen_noflow">Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wiegand J, Tischendorf JJ, Nashan B, Klempnauer J, Flemming P, Niemann P, Rohde P, Manns MP, Trautwein C, Tillmann HL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Z Gastroenterol. 2004 Jan; 42(1):15-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14699491" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.</a><span class="source">[Gastroenterology. 2004]</span><div class="brieflinkpop offscreen_noflow">Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Gastroenterology. 2004 Jan; 126(1):91-101. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15500383" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adefovir dipivoxil in chronic hepatitis B infection.</a><span class="source">[Expert Opin Pharmacother. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adefovir dipivoxil in chronic hepatitis B infection.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Yuen MF, Lai CL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Expert Opin Pharmacother. 2004 Nov; 5(11):2361-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14646571" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].</a><span class="source">[Korean J Gastroenterol. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> [Application and efficacy of adefovir dipivoxil in hepatitis B virus-associated chronic liver diseases].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Cho YK, Kim BI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Korean J Gastroenterol. 2003 Nov; 42(5):357-62. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14498759" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adefovir dipivoxil: a review of its use in chronic hepatitis B.</a><span class="source">[Drugs. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Adefovir dipivoxil: a review of its use in chronic hepatitis B.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Dando T, Plosker G. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drugs. 2003; 63(20):2215-34. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643945" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643945" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=604675189e31203af62a2eea">Adefovir - LiverTox</a><div class="ralinkpop offscreen_noflow">Adefovir - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T14:03:52-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B320904669E3100000000027E00C5&amp;ncbi_session=CE8B320904675171_0638SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548633%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548633&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548633/&amp;ncbi_pagename=Adefovir - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B320904675171_0638SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>